These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12127513)

  • 1. Efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivative, a selective agonist for human peroxisome proliferator-activated receptor alpha.
    Nomura M; Tanase T; Miyachi H
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2101-4. PubMed ID: 12127513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concise and efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivatives: dual agonists for human peroxisome proliferator-activated receptor alpha and delta.
    Kasuga J; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2006 Feb; 16(4):771-4. PubMed ID: 16321522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor alpha.
    Miyachi H; Nomura M; Tanase T; Suzuki M; Murakami K; Awano K
    Bioorg Med Chem Lett; 2002 Feb; 12(3):333-5. PubMed ID: 11814790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators.
    Miyachi H; Nomura M; Tanase T; Takahashi Y; Ide T; Tsunoda M; Murakami K; Awano K
    Bioorg Med Chem Lett; 2002 Jan; 12(1):77-80. PubMed ID: 11738577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
    Nomura M; Tanase T; Ide T; Tsunoda M; Suzuki M; Uchiki H; Murakami K; Miyachi H
    J Med Chem; 2003 Aug; 46(17):3581-99. PubMed ID: 12904063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the critical structural determinant(s) of species-selective peroxisome proliferator-activated receptor alpha (PPAR alpha)-activation by phenylpropanoic acid-type PPAR alpha agonists.
    Miyachi H; Uchiki H
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3145-9. PubMed ID: 12951082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
    Ebdrup S; Pettersson I; Rasmussen HB; Deussen HJ; Frost Jensen A; Mortensen SB; Fleckner J; Pridal L; Nygaard L; Sauerberg P
    J Med Chem; 2003 Apr; 46(8):1306-17. PubMed ID: 12672231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling study of species-selective peroxisome proliferator-activated receptor (PPAR) alpha agonist; possible mechanism(s) of human PPARalpha selectivity of an alpha-substituted phenylpropanoic acid derivative (KCL).
    Uchiki H; Miyachi H
    Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):365-7. PubMed ID: 14993764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.
    Xu Y; Rito CJ; Etgen GJ; Ardecky RJ; Bean JS; Bensch WR; Bosley JR; Broderick CL; Brooks DA; Dominianni SJ; Hahn PJ; Liu S; Mais DE; Montrose-Rafizadeh C; Ogilvie KM; Oldham BA; Peters M; Rungta DK; Shuker AJ; Stephenson GA; Tripp AE; Wilson SB; Winneroski LL; Zink R; Kauffman RF; McCarthy JR
    J Med Chem; 2004 May; 47(10):2422-5. PubMed ID: 15115385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
    Kasuga J; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2006 Feb; 16(3):554-8. PubMed ID: 16275077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists.
    Ban S; Kasuga J; Nakagome I; Nobusada H; Takayama F; Hirono S; Kawasaki H; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2011 May; 19(10):3183-91. PubMed ID: 21530275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and in vitro evaluation of a series of α-substituted phenylpropanoic acid PPARγ agonists to further investigate the stereochemistry-activity relationship.
    Ohashi M; Nakagome I; Kasuga J; Nobusada H; Matsuno K; Makishima M; Hirono S; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2012 Nov; 20(21):6375-83. PubMed ID: 23022278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta.
    Wei ZL; Kozikowski AP
    J Org Chem; 2003 Nov; 68(23):9116-8. PubMed ID: 14604391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship.
    Ohashi M; Oyama T; Nakagome I; Satoh M; Nishio Y; Nobusada H; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
    J Med Chem; 2011 Jan; 54(1):331-41. PubMed ID: 21128600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of ragaglitazar, a novel dual acting peroxisome proliferator-activated receptor (PPAR) alpha and -gamma agonist, in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry.
    Andersen MP; Nielsen KK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):45-55. PubMed ID: 12668070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility.
    Ohashi M; Oyama T; Putranto EW; Waku T; Nobusada H; Kataoka K; Matsuno K; Yashiro M; Morikawa K; Huh NH; Miyachi H
    Bioorg Med Chem; 2013 Apr; 21(8):2319-2332. PubMed ID: 23490155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
    Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.
    Lohray BB; Lohray VB; Bajji AC; Kalchar S; Poondra RR; Padakanti S; Chakrabarti R; Vikramadithyan RK; Misra P; Juluri S; Mamidi NV; Rajagopalan R
    J Med Chem; 2001 Aug; 44(16):2675-8. PubMed ID: 11472221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
    Henke BR
    J Med Chem; 2004 Aug; 47(17):4118-27. PubMed ID: 15293980
    [No Abstract]   [Full Text] [Related]  

  • 20. [Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands].
    Miyachi H
    Yakugaku Zasshi; 2004 Nov; 124(11):803-13. PubMed ID: 15516807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.